BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 36281681)

  • 1. Evaluation of the Fiscal Costs and Consequences of Alzheimer's Disease in Germany: Microsimulation of Patients' and Caregivers' Pathways.
    Martins R; Kotsopoulos N; Michalowsky B; Pemberton-Ross P; Urbich M; Connolly MP
    J Prev Alzheimers Dis; 2022; 9(4):758-768. PubMed ID: 36281681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Hidden Economic Consequences of Migraine to the UK Government: Burden-of-Disease Analysis Using a Fiscal Framework.
    Martins R; Large S; Russell R; Surmay G; Connolly MP
    J Health Econ Outcomes Res; 2023; 10(2):72-81. PubMed ID: 37808457
    [No Abstract]   [Full Text] [Related]  

  • 3. Estimating the broader fiscal consequences of acute hepatic porphyria (AHP) with recurrent attacks in Belgium using a public economic analytic framework.
    Connolly MP; Kotsopoulos N; Vermeersch S; Patris J; Cassiman D
    Orphanet J Rare Dis; 2021 Aug; 16(1):346. PubMed ID: 34348763
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessing the Fiscal Burden of Obesity in Canada by Applying a Public Economic Framework.
    Kotsopoulos N; Connolly MP
    Adv Ther; 2024 Jan; 41(1):379-390. PubMed ID: 37979088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The fiscal consequences of public health investments in disease-modifying therapies for the treatment of multiple sclerosis in Sweden.
    Kotsopoulos N; Connolly MP; Dort T; Kavaliunas A
    J Med Econ; 2020 Aug; 23(8):831-837. PubMed ID: 32400258
    [No Abstract]   [Full Text] [Related]  

  • 6. The fiscal consequences of ADHD in Germany: a quantitative analysis based on differences in educational attainment and lifetime earnings.
    Kotsopoulos N; Connolly MP; Sobanski E; Postma MJ
    J Ment Health Policy Econ; 2013 Mar; 16(1):27-33. PubMed ID: 23676413
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Lifetime Burden of Schizophrenia as Estimated by a Government-Centric Fiscal Analytic Framework.
    Martins R; Kadakia A; Williams GR; Milanovic S; Connolly MP
    J Clin Psychiatry; 2023 Aug; 84(5):. PubMed ID: 37555674
    [No Abstract]   [Full Text] [Related]  

  • 8. Family and Caregiver Spillover Effects in Cost-Utility Analyses of Alzheimer's Disease Interventions.
    Lin PJ; D'Cruz B; Leech AA; Neumann PJ; Sanon Aigbogun M; Oberdhan D; Lavelle TA
    Pharmacoeconomics; 2019 Apr; 37(4):597-608. PubMed ID: 30903567
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modeling the fiscal costs and benefits of alternative treatment strategies in the United Kingdom for chronic hepatitis C.
    Connolly MP; Kotsopoulos N; Ustianowski A
    J Med Econ; 2018 Jan; 21(1):19-26. PubMed ID: 28830254
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 2024 Alzheimer's disease facts and figures.
    Alzheimers Dement; 2024 May; 20(5):3708-3821. PubMed ID: 38689398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The long-term fiscal impact of funding cuts to Danish public fertility clinics.
    Connolly MP; Postma MJ; Crespi S; Andersen AN; Ziebe S
    Reprod Biomed Online; 2011 Dec; 23(7):830-7. PubMed ID: 22033399
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparing the Fiscal Consequences of Controlled and Uncontrolled Osteoarthritis Pain Applying a UK Public Economic Perspective.
    Martins R; Kotsopoulos N; Kosaner Kließ M; Beck C; Abraham L; Large S; Schepman P; Connolly MP
    J Health Econ Outcomes Res; 2021; 8(1):127-136. PubMed ID: 34239946
    [No Abstract]   [Full Text] [Related]  

  • 13. Estimating the public economic consequences of introducing varenicline smoking cessation therapy in South Korea using a fiscal analytic framework.
    Connolly MP; Baker CL; Kotsopoulos N
    J Med Econ; 2018 Jun; 21(6):571-576. PubMed ID: 29376747
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estimating the public economic consequences of cardiovascular disease-attributable events and evolocumab treatment in Australia.
    Kotsopoulos N; Connolly MP; Li J
    J Med Econ; 2021; 24(1):123-130. PubMed ID: 33464137
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estimating the fiscal impact of rare diseases using a public economic framework: a case study applied to hereditary transthyretin-mediated (hATTR) amyloidosis.
    Connolly MP; Panda S; Patris J; Hazenberg BPC
    Orphanet J Rare Dis; 2019 Sep; 14(1):220. PubMed ID: 31533773
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The public economic burden of suboptimal type 2 diabetes control upon taxpayers in Sweden: Looking beyond health costs.
    Kotsopoulos N; Connolly MP; Willis M; Nilsson A; Ericsson Å; Baker-Knight J
    Diabetes Obes Metab; 2022 Jun; 24(6):1038-1046. PubMed ID: 35137507
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 2023 Alzheimer's disease facts and figures.
    Alzheimers Dement; 2023 Apr; 19(4):1598-1695. PubMed ID: 36918389
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The fiscal impact of informal caregiving to home care recipients in Canada: how the intensity of care influences costs and benefits to government.
    Jacobs JC; Lilly MB; Ng C; Coyte PC
    Soc Sci Med; 2013 Mar; 81():102-9. PubMed ID: 23347496
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of rotavirus vaccination on discounted net tax revenue in Egypt: a government perspective analysis.
    Connolly MP; Topachevskyi O; Standaert B; Ortega O; Postma M
    Pharmacoeconomics; 2012 Aug; 30(8):681-95. PubMed ID: 22788259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estimating the Fiscal Costs of Osteoporosis in Korea Applying a Public Economic Perspective.
    Connolly MP; Panda S; Kim HY
    J Bone Metab; 2019 Nov; 26(4):253-261. PubMed ID: 31832391
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.